Literature DB >> 19521663

Depression and antidepressants: molecular and cellular aspects.

Cristina Lanni1, Stefano Govoni, Adele Lucchelli, Cinzia Boselli.   

Abstract

Clinical depression is viewed as a physical and psychic disease process having a neuropathological basis, although a clear understanding of its ethiopathology is still missing. The observation that depressive symptoms are influenced by pharmacological manipulation of monoamines led to the hypothesis that depression results from reduced availability or functional deficiency of monoaminergic transmitters in some cerebral regions. However, there are limitations to current monoamine theories related to mood disorders. Recently, a growing body of experimental data has showed that other classes of endogenous compounds, such as neuropeptides and amino acids, may play a significant role in the pathophysiology of affective disorders. With the development of neuroscience, neuronal networks and intracellular pathways have been identified and characterized, describing the existence of the interaction between monoamines and receptors in turn able to modulate the expression of intracellular proteins and neurotrophic factors, suggesting that depression/antidepressants may be intermingled with neurogenesis/neurodegenerative processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521663     DOI: 10.1007/s00018-009-0055-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  271 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Authors:  Cristiana Griffante; Andrew Green; Ornella Curcuruto; Carl P Haslam; Bryony A Dickinson; Roberto Arban
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Increased vasopressinergic activity as a possible compensatory mechanism for a normal hypothalamic-pituitary-adrenal axis response to stress in BALB/c nude mice.

Authors:  E Spinedi; R Hadid; R C Gaillard
Journal:  Neuroendocrinology       Date:  1997-10       Impact factor: 4.914

4.  Fluoxetine inhibits ATP-induced [Ca(2+)](i) increase in PC12 cells by inhibiting both extracellular Ca(2+) influx and Ca(2+) release from intracellular stores.

Authors:  Hee Jung Kim; Jin Sung Choi; Yeo-Min Lee; Eun Young Shim; Sun Hwa Hong; Myung-Jun Kim; Do Sik Min; Duck-Joo Rhie; Myung-Suk Kim; Yang-Hyeok Jo; Sang June Hahn; Shin Hee Yoon
Journal:  Neuropharmacology       Date:  2005-08       Impact factor: 5.250

Review 5.  Norepinephrine in depressive reactions. A review.

Authors:  W E Bunney; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1965-12

6.  V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.

Authors:  R Landgraf; R Gerstberger; A Montkowski; J C Probst; C T Wotjak; F Holsboer; M Engelmann
Journal:  J Neurosci       Date:  1995-06       Impact factor: 6.167

Review 7.  Cholinergic receptor subtypes and REM sleep in animals and normal controls.

Authors:  J C Gillin; R Salin-Pascual; J Velazquez-Moctezuma; P Shiromani; R Zoltoski
Journal:  Prog Brain Res       Date:  1993       Impact factor: 2.453

Review 8.  Toward a molecular neuropsychiatry of neurodegenerative diseases.

Authors:  Jeffrey L Cummings
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

Review 9.  GABA and behavior: the role of receptor subtypes.

Authors:  R G Paredes; A Agmo
Journal:  Neurosci Biobehav Rev       Date:  1992       Impact factor: 8.989

Review 10.  Neurokinin 1 receptor antagonists--current prospects.

Authors:  Giuseppe Alvaro; Romano Di Fabio
Journal:  Curr Opin Drug Discov Devel       Date:  2007-09
View more
  20 in total

1.  The monoaminergic modulation of sensory-mediated aversive responses in Caenorhabditis elegans requires glutamatergic/peptidergic cotransmission.

Authors:  Gareth Harris; Holly Mills; Rachel Wragg; Vera Hapiak; Michelle Castelletto; Amanda Korchnak; Richard W Komuniecki
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Cadmium, Lead, and Depressive Symptoms: Analysis of National Health and Nutrition Examination Survey 2011-2012.

Authors:  Melanie C Buser; Franco Scinicariello
Journal:  J Clin Psychiatry       Date:  2017-05       Impact factor: 4.384

3.  Blood cadmium and depressive symptoms in young adults (aged 20-39 years).

Authors:  F Scinicariello; M C Buser
Journal:  Psychol Med       Date:  2014-08-13       Impact factor: 7.723

Review 4.  Do we need pharmacogenetics to personalize antidepressant therapy?

Authors:  Cristina Lanni; Marco Racchi; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2012-12-28       Impact factor: 9.261

Review 5.  Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?

Authors:  Francesca Pistoia; Elisa Mura; Stefano Govoni; Massimo Fini; Marco Sarà
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

6.  Insulin resistance in brain alters dopamine turnover and causes behavioral disorders.

Authors:  Andre Kleinridders; Weikang Cai; Laura Cappellucci; Armen Ghazarian; William R Collins; Sara G Vienberg; Emmanuel N Pothos; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

7.  Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats.

Authors:  R Vidal; E M Valdizan; M T Vilaró; A Pazos; E Castro
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

8.  Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder.

Authors:  Nunzio Pomara; Davide Bruno; Antero S Sarreal; Raymundo T Hernando; Jay Nierenberg; Eva Petkova; John J Sidtis; Thomas M Wisniewski; Pankaj D Mehta; Domenico Pratico; Henrik Zetterberg; Kaj Blennow
Journal:  Am J Psychiatry       Date:  2012-05       Impact factor: 18.112

9.  The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies.

Authors:  William V Bobo; Richard A Epstein; Rachel M Hayes; Richard C Shelton; Tina V Hartert; Ed Mitchel; Jeff Horner; Pingsheng Wu
Journal:  Arch Womens Ment Health       Date:  2013-10-03       Impact factor: 3.633

Review 10.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.